Home
About Us
Our Products
Patient Assistance Program
Responsibility and Compliance
Frequently Asked Questions
Press and Media
Information About the ENHANCE Trial
MERCK/Schering-Plough Pharmaceuticals

Information About the ENHANCE Trial

Merck / Schering-Plough Press Releases

Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study - 03/30/08
Results from ENHANCE Study - 03/30/08
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial – 01/25/08
ENHANCE Chronology – 01/25/08
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial – 01/14/08
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial – 11/19/07
Product Information and Patient Information for VYTORIN® (ezetimibe/simvastatin)
Product Information and Patient Information for ZETIA® (ezetimibe)

Information From Merck and Schering-Plough

Message to Patients about Recent News on VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) – 01/19/08
Product Information and Patient Information for VYTORIN® (ezetimibe/simvastatin)
Product Information and Patient Information for ZETIA® (ezetimibe)

FDA Communications

FDA Issues Early Communciation about an Ongoing Review of VYTORIN
Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as VYTORIN),
Ezetimibe (marketed as ZETIA), and Simvastatin (marketed as Zocor)
Transcript of FDA Press Conference on Early Communication about an Ongoing Review of VYTORIN
Product Information and Patient Information for VYTORIN® (ezetimibe/simvastatin)
Product Information and Patient Information for ZETIA® (ezetimibe)